Floatz logo

Cypep-1

Advanced Solid Tumor Malignancy

Cytovation ASPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Advanced Solid Tumor Malignancy cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kling Biotherapeutics B.V.
Phase 1/2B
Evomela
University of Washington
Phase 2B
Cladribine
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
CYCLOSPORIN A
University of Washington
Phase 2B

View all 18 →

Same molecule, other indications

Cypep-1 is also rated in:

head and neck squamous cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →
melanomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →